Has Freddie Toffel received payments from drug or device companies?

Yes. Drug and device makers reported $33,000 in general payments to Freddie Toffel across 100 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Freddie Toffel did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Freddie Toffel come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Freddie Toffel

Endocrinology, Diabetes & Metabolism · Las Vegas, NVNPI 1194877514

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,080 of the $33,000 with a category attached, or 63.9%. Novo Nordisk accounts for 85.5% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $25,908 and has fallen 97.1% since, to $746 in 2025.

$33,000in general payments, 2019–2025

Across 100 payments — averaging $330.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$28K
AstraZeneca$914
Amgen$440
Corcept Therapeutics$377
Chiesi USA, Inc.$353
AbbVie$311
plus $2K from 22 others

What the payments were for

Consulting fees$4,84515%
Speaking & faculty fees$21,08064%
Travel & lodging$1,6165%
Food & beverage$5,45117%
Education$80%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	33	$28,205
AstraZeneca(2 entities)	15	$914
Amgen(2 entities)	6	$440
Corcept Therapeutics	3	$377
Chiesi USA, Inc.	3	$353
AbbVie	4	$311
Lilly USA, LLC	5	$244
Sanofi-aventis U.S. LLC	2	$211
Medtronic	2	$161
Tandem Diabetes Care, Inc.	3	$150
Amarin Pharma, Inc.	3	$143
Neurocrine Biosciences, Inc.	1	$138
Xeris Pharmaceuticals, Inc.	1	$135
Kyowa Kirin, Inc.	1	$128
Ascendis Pharma Endocrinology Inc	1	$125
Bayer	1	$125
Gilead	1	$124
Ipsen Biopharmaceuticals, Inc	1	$117
Merck	2	$114
Dexcom, Inc.	2	$113
Esperion Therapeutics, Inc.	1	$109
Recordati_rare_diseases_inc.	1	$88
Insulet Corporation	2	$67
Bard Peripheral Vascular, Inc.	1	$38
Boehringer Ingelheim	2	$33
Radius Health, Inc.	1	$17
Janssen Scientific Affairs, LLC	1	$14
Cardiovascular Systems Inc.	1	$5

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,000 in reported general payments places this provider in the 80th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.

See all endocrinology, diabetes & metabolism providers in Nevada →

Other endocrinology, diabetes & metabolism in Las Vegas

Samer NakhleLas Vegas$466K
Chakravarthy KannanLas Vegas$144K
Michael UzmannLas Vegas$77K
Molouk RahnemaLas Vegas$73K
Nicholas VernettiLas Vegas$62K
Firhaad IsmailLas Vegas$47K
Bijan AhrariLas Vegas$47K
Serena KlughLas Vegas$14K
Betsy PalalLas Vegas$9K
Amber ChampionLas Vegas$9K

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →